Skip to main content
. 2019 Feb 1;11(2):170. doi: 10.3390/cancers11020170

Table 2.

Summary of tracers used in preclinical studies and their biological targets.

Tracer Targeting Moiety Biological Target Reference
64Cu Anti-PD-1 Tumor infiltrating lymphocytes [41]
124I Anti-CD4 CD8+ cells [42,43,44]
89Zr Anti-CD4 T-cell reconstitution post-transplant [43]
89Zr Anti-CD3 tumor-infiltrating lymphocytes [44]
64Cu Anti-OX40 T cells activation [45]
Anti-CTLA-4 CTLA-4 visualization
68Ga/18F PSMA PSMA [46]
18F-FDG Fluorodeoxyglucose Glucose metabolism [47]
68Ga-NODAGA-c(RGDfK) RGD (arginine, glycine, aspartate) peptides αvβ3 integrins in the tumor vasculature [48]
18F-EF5 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoro propyl)-acetamide Hypoxia [49,50]
18F-FAZA 1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole
18F-FMISO Fluoromisonidazole [51,52,53,54]
18F-HX4 fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol
(18F)F-AraG 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoro propyl)-acetamide
fluoro-9-β-D-arabinofuranosyl guanin
T cell activation [55,56]